Fisher Asset Management LLC Purchases 1,150 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Fisher Asset Management LLC grew its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 22.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,305 shares of the biotechnology company’s stock after buying an additional 1,150 shares during the quarter. Fisher Asset Management LLC’s holdings in United Therapeutics were worth $2,259,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. LSV Asset Management grew its position in United Therapeutics by 82.5% during the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after acquiring an additional 436,851 shares during the last quarter. Assetmark Inc. increased its stake in shares of United Therapeutics by 56.9% in the third quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock valued at $150,492,000 after buying an additional 152,249 shares in the last quarter. Pacer Advisors Inc. raised its holdings in shares of United Therapeutics by 19.6% in the second quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock valued at $178,972,000 after buying an additional 92,240 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in United Therapeutics by 49.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 276,531 shares of the biotechnology company’s stock worth $88,089,000 after buying an additional 91,597 shares in the last quarter. Finally, Candriam S.C.A. grew its holdings in United Therapeutics by 2,094.3% during the 2nd quarter. Candriam S.C.A. now owns 64,513 shares of the biotechnology company’s stock worth $20,550,000 after acquiring an additional 61,573 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on UTHR. Argus upped their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. HC Wainwright increased their price objective on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Jefferies Financial Group lifted their target price on United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. TD Cowen upped their price target on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Finally, Wells Fargo & Company lifted their price objective on United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $370.86.

United Therapeutics Price Performance

United Therapeutics stock opened at $370.49 on Friday. The firm has a market capitalization of $16.54 billion, a price-to-earnings ratio of 16.37, a PEG ratio of 1.10 and a beta of 0.56. The company’s 50 day simple moving average is $367.42 and its 200 day simple moving average is $334.45. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. During the same period last year, the firm posted $5.38 earnings per share. The business’s quarterly revenue was up 22.9% compared to the same quarter last year. As a group, analysts predict that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other news, Director Judy D. Olian sold 1,750 shares of the stock in a transaction on Monday, November 11th. The shares were sold at an average price of $412.48, for a total transaction of $721,840.00. Following the completion of the sale, the director now owns 5,655 shares of the company’s stock, valued at $2,332,574.40. This represents a 23.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $372.75, for a total transaction of $3,727,500.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at $960,576.75. This represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 127,227 shares of company stock valued at $47,398,820. Company insiders own 11.90% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.